Venus Remedies Limited (VENUSREM) AI Stock Analysis

• Market Cap: ₹11.54B
• Dividend Yield: N/A
• Average Volume (3M): 2.33K
• Price to Earnings (P/E): 10.0
• Beta (1Y): 1.11
• Revenue Growth: 13.32%
• EPS Growth: 218.38%
• Country: IN
• Employees: 1,187
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 19.14
• Shares Outstanding: 13,366,988
• 10 Day Avg. Volume: 2,529
• 30 Day Avg. Volume: 2,330
• PEG Ratio: 0.16
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.65
• P/FCF Ratio: 5.20
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹967.00 ▲(23.62% Upside)
• Action: Reiterated Date: 03/12/26
• Date: Action: Reiterated 03/12/26

The score is driven primarily by strong financial performance (growth, profitability improvements, low leverage, and strong free cash flow). Technicals remain supportive due to the uptrend versus major moving averages, though negative MACD tempers the outlook. Valuation is reasonable on P/E, but the absence of dividend yield data limits additional upside to the score.

Positive Factors

Strong free cash flow

Sustained positive free cash flow signals durable internal funding for R&D, capacity expansion, and deleveraging. Strong operating cash conversion reduces reliance on external financing and supports long-term investment in hospital/critical-care product lines, improving strategic optionality.

Low financial leverage

A high equity ratio and favorable debt-to-equity indicate financial resilience through economic cycles. Low leverage preserves borrowing capacity, limits interest expense volatility, and reduces refinancing risk, supporting consistent operations and funding of growth initiatives over the medium term.

Improving revenue and margins

Consistent revenue growth alongside expanding gross and net margins reflects effective cost management and stronger product mix. Durable margin improvement supports higher internal cash generation and signals competitive positioning in hospital/critical-care and anti-infective segments over several quarters.

Negative Factors

Concentration in hospital/anti-infectives

Heavy exposure to hospital and anti-infective products creates concentration risk: regulatory shifts, antimicrobial stewardship programs, or pricing pressure in these segments could materially affect revenues. Limited product diversification raises sensitivity to segment-specific policy and competition.

Low trading liquidity

Very low average trading volume can impede large institutional transactions and make share exits more difficult without price impact. Structural illiquidity may deter long-term investors who require portfolio flexibility and can amplify volatility when sizable shareholders trade.

Limited income-supporting dividend data

Absence of disclosed dividend yield suggests limited or uncertain cash returns to shareholders, reducing appeal for income-focused investors. Over the medium term this can constrain shareholder base diversity and pressure management to prioritize cash uses carefully between capex, buybacks, and payouts.

Venus Remedies Limited Business Overview & Revenue Model

Company Description

Venus Remedies Limited develops and markets pharmaceutical products in India and internationally. The company offers its products in various therapeutic areas, such as analgesic, analgesic and antipyretic, anti-diabetic, antibiotic, anticoagulant, cardiac, disinfectant and antiseptic, gastro therapy, hand sanitizers, hormones, iron supplements, neurology, oncology, pain management, respiratory, skin and wound care, stress reliever, urology, and vitamins/minerals/nutrients, as well as antimicrobial resistance products. It also provides disinfectants; and a portfolio of herbal products. Venus Remedies Limited was incorporated in 1989 and is headquartered in Panchkula, India.

How the Company Makes Money

Venus Remedies makes money primarily by selling pharmaceutical products. Its main revenue stream is the manufacture and sale of finished formulations—especially hospital and critical-care medicines (notably anti-infectives/antibiotics)—to customers in India and overseas through its own marketing/distribution channels and/or third-party distribution networks. A secondary revenue stream comes from supplying products to other pharmaceutical companies under contract manufacturing and/or out-licensing/technology transfer arrangements where applicable (specific counterparties and deal terms: null). International revenues are supported by registrations/approvals in multiple markets and exports of its product portfolio (market-wise split: null). Other operating income sources (e.g., APIs, services, or grants) are not reliably specified here and are therefore: null.

Venus Remedies Limited Financial Statement Overview

Summary

Strong overall fundamentals supported by solid income statement performance (revenue growth, improved net profitability, healthy EBIT/EBITDA margins), a stable balance sheet with low leverage and improving ROE, and strong cash generation with rising free cash flow and good earnings-to-cash conversion.

Income Statement

Venus Remedies Limited has demonstrated strong revenue growth over the years, with a significant increase from 2020 to 2025. The company maintains a healthy Gross Profit Margin, indicating efficient production and cost management. The Net Profit Margin has improved significantly compared to earlier losses, reflecting enhanced operational efficiency and profitability. The EBIT and EBITDA margins are solid, showcasing robust earnings performance before interest, taxes, and non-cash expenses.

Balance Sheet

The company displays a strong equity position with a high Equity Ratio, suggesting financial stability and a low reliance on debt. The Debt-to-Equity Ratio is favorable, indicating low financial leverage and reduced risk of financial distress. Return on Equity has shown consistent improvement, reflecting effective use of shareholders' equity in generating profits.

Cash Flow

Venus Remedies Limited exhibits strong cash flow performance, with a significant positive Free Cash Flow trend, indicating good cash generation after capital expenditures. The Operating Cash Flow to Net Income Ratio is robust, highlighting efficient conversion of earnings into cash. There is a significant increase in Free Cash Flow over the years, underscoring the company's strong cash-generating capabilities.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.71B	6.48B	5.91B	5.56B	5.99B	5.48B
Gross Profit	2.22B	1.66B	2.18B	2.25B	2.00B	1.07B
EBITDA	1.00B	944.10M	711.80M	703.46M	701.40M	968.49M
Net Income	537.10M	453.20M	284.91M	265.70M	407.24M	617.65M
Balance Sheet
Total Assets	0.00	7.16B	6.27B	6.01B	5.80B	5.56B
Cash, Cash Equivalents and Short-Term Investments	1.56B	1.64B	838.05M	720.77M	432.56M	288.79M
Total Debt	0.00	16.90M	413.25M	422.90M	428.45M	513.18M
Total Liabilities	-5.61B	1.55B	1.39B	1.41B	1.39B	1.56B
Stockholders Equity	5.61B	5.61B	4.88B	4.60B	4.40B	4.00B
Cash Flow
Free Cash Flow	0.00	812.90M	278.40M	288.02M	272.94M	1.25B
Operating Cash Flow	0.00	909.20M	372.85M	366.20M	410.01M	1.33B
Investing Cash Flow	0.00	-807.90M	-72.09M	-508.30M	-166.26M	557.16M
Financing Cash Flow	0.00	-9.50M	-10.83M	-5.70M	-94.77M	-1.62B

Venus Remedies Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 782.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VENUSREM, the sentiment is Positive. The current price of 782.25 is above the 20-day moving average (MA) of 733.49, above the 50-day MA of 745.56, and above the 200-day MA of 574.29, indicating a bullish trend. The MACD of 5.31 indicates Negative momentum. The RSI at 68.53 is Neutral, neither overbought nor oversold. The STOCH value of 94.64 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VENUSREM.

Venus Remedies Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	74 Outperform	₹11.54B	10.01	―	―	13.32%	218.38%
ZIMLAB	63 Neutral	₹3.29B	19.99	―	―	-5.82%	-59.22%
INDSWFTLAB	61 Neutral	₹11.69B	18.86	―	―	-37.70%	-19.79%
KILITCH	57 Neutral	₹5.54B	34.53	―	―	32.95%	67.39%
MEDICAMEQ	57 Neutral	₹3.84B	56.53	―	0.26%	-9.16%	49.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NECLIFE	46 Neutral	₹2.56B	7.63	―	―	-30.27%	-3470.06%

Venus Remedies Limited Corporate Events

Venus Remedies Alerts Shareholders to Special Window for Physical Share Transfer Requests

Venus Remedies has notified stock exchanges that it has used its official social media channels to inform shareholders about a special window for re-lodgement of transfer requests for physical shares. The communication aligns with recent Securities and Exchange Board of India guidelines, signaling the company’s efforts to ensure regulatory compliance and improve investor awareness around legacy physical share transfers, which may affect how some investors regularise their holdings.

Venus Remedies Publishes Unaudited Q3 FY2025 Financial Results in Newspapers

Venus Remedies Limited has notified the stock exchange that it has published its unaudited financial results for the period ended 31 December 2025 in newspapers, in compliance with disclosure requirements under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR). The move underscores the company’s adherence to statutory transparency and reporting norms, providing stakeholders with timely access to its quarterly financial performance and reinforcing its governance and compliance standards in the pharmaceutical sector.

Venus Remedies Closes Trading Window Ahead of December 2025 Results

Venus Remedies Limited has announced that, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, its trading window for dealing in the company’s securities will be closed for all designated persons from January 1, 2026 until 48 hours after the declaration of its audited financial results for the period ending December 31, 2025. The move is a routine compliance step aimed at preventing insider trading around the release of key financial information, reinforcing the company’s adherence to regulatory standards and safeguarding transparency for investors and other market participants.

Venus Remedies Opens Special Window for Share Transfer Requests

Venus Remedies Limited has announced the opening of a special window for the re-lodgement of transfer requests for physical shares. This move is in compliance with a SEBI circular issued in July 2025, and the company has communicated this update through its official social media channels. The initiative reflects Venus Remedies’ commitment to adhering to regulatory requirements and ensuring smooth operations for its shareholders.